Process for synthesizing apremilast
Patent Information
- Application Number
- TW111115570
- Authority / Receiving Office
- TW · TW
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-04-26
- Filing Date
- 2022-04-25
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2042-04-24
AI Technical Summary
Existing methods for synthesizing apremilast are inefficient, requiring long reaction times, multiple aqueous work-up steps, and result in significant waste generation, making them unsuitable for scalable and cost-effective production.
A continuous method involving the acid-catalyzed condensation of 3-acetamidophthalic anhydride and (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethan-1-amine in a polar aprotic solvent like DMSO, followed by direct crystallization in a mixed suspension mixed product removal (MSMPR) crystallizer, reduces reaction time and minimizes waste.
The method achieves faster reaction times, reduces waste, and allows for efficient isolation of crystalline apremilast without intermediate processing steps, making it suitable for industrial-scale production.
Smart Images

Figure TWG2TB001919946_001 
Figure TWG2TB001919946_002 
Figure TWG2TB001919946_003
Abstract
Description
Technical Field
[0001] This document discloses a method for synthesizing (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylutriethyl]-4-acetylaminoisoindoline-1,3-dione (apremilast), wherein embodiments of the method relate to both continuous and batch methods for synthesizing apremilast. Prior Technology
[0002] Aprestigmine is a member of the isoindolinoid class, with an acetaminophen group substituted at position 4 and a 1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonylurea)ethyl group substituted at position 1. It functions as a phosphodiesterase IV inhibitor and a nonsteroidal anti-inflammatory drug, and has the following chemical structure: Apst
[0003] Apster can be formed via an acid-catalyzed condensation reaction between 3-acetaminophthalic anhydride (compound A) and (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonylurea)ethyl-1-amine (compound B). The chemical structures of compounds A and B are as follows: (Compound A) (Compound B)
[0004] The reaction can proceed in various ways. One such example is the acid-catalyzed condensation of compound (A) and compound (B) in an organic solvent (e.g., tetrahydrofuran, or THF) containing a catalytic amount of water. This acid-catalyzed reaction requires heating the reaction mixture at 72°C for approximately 16 hours to produce crude apremilast. Separation of the crude product from the reaction mixture then requires a series of aqueous treatment steps, followed by distillation, and finally crystallization from a solvent mixture such as isopropyl acetate / methyl tributyl ether.
[0005] There is a demand for methods for producing Apstar that benefit from reduced cycle time due to shortened reaction time, less waste generation by reducing water treatment steps, and smaller and more flexible manufacturing space requirements. Summary of the Invention
[0006] This document provides methods for preparing aprestil, comprising mixing (1) a first solution of 3-acetaminophen phthalic anhydride (compound A) or a salt thereof contained in a first solvent and (2) a second solution of (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonylmethane)ethyl-1-amine (compound B) or a salt thereof contained in a second solvent to form aprestil in a reaction mixture; and adding water to the reaction mixture to separate the aprestil. In various embodiments, the mixing occurs in a plug flow reactor.
[0007] In some embodiments, the mixing is carried out in the presence of an acid. In some embodiments, the acid is an alkyl sulfonic acid, an aryl sulfonic acid, an alkyl carboxylic acid, or an aryl carboxylic acid. In some embodiments, the acid is selected from the group consisting of acetic acid, methanesulfonic acid, toluenesulfonic acid, trifluoroacetic acid, trichloroacetic acid, dichloroacetic acid, chloroacetic acid, benzenesulfonic acid, trifluoromethanesulfonic acid, ethyl sulfonic acid, formic acid, propionic acid, benzoic acid, salicylic acid, and oxalic acid. In some embodiments, the acid comprises acetic acid. The acid can be present in a volume equivalent of 0.01 to 20 (or 0.5 to 3, or 1 to 2.5) of compound B or its salt.
[0008] In some embodiments, the mixing is carried out in the presence of up to 1.5 (or 0.5) molar equivalents of water based on compound B or its salt, while in other embodiments, the mixing is carried out in the absence of water.
[0009] In various embodiments, compound A or a salt thereof is present in an amount of 0.4 to 1.5 (or 0.8 to 1.2, or 0.99) molar equivalents based on compound B or a salt thereof. In various embodiments, compound A is present as a neutral substance (i.e., not in salt form). In various embodiments, compound B is present as a neutral substance (i.e., not in salt form), while in other embodiments, compound B is present in salt form.
[0010] In various embodiments, the first solvent and the second solvent are the same solvent, while in other embodiments, the first solvent and the second solvent are different solvents. In various embodiments, the first solvent and / or the second solvent are polar aprotic solvents. In various embodiments, the polar aprotic solvent has a boiling point of about 40°C to about 200°C at 1 atm. In various embodiments, the polar aprotic solvent contains 0-10% water by weight, while in other embodiments, the polar aprotic solvent is anhydrous. In various embodiments, the polar aprotic solvent has a dielectric constant of 10 to 50 at room temperature and 1 atm. In various embodiments, the polar aprotic solvent is acetonitrile, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMAC), N-methyl-2-pyrrolidone (NMP), hexamethylphosphonamide (HMPA), N,N′-dimethylpropylideneurea (DMPU), cyclobutane, dihydro-L-glucosidone, 1,3-dimethyl-2-imidazolinone (DMI), or combinations thereof. In various embodiments, the polar aprotic solvent comprises DMSO.
[0011] In various embodiments, the mixing is carried out at temperatures ranging from 20°C to 200°C, 50°C to 200°C, 70°C to 190°C, 130°C to 135°C, or from 70°C to solvent reflux. In some embodiments, the mixing occurs with reaction times of 0.1 min to 48 hr, or 4 hr to 36 hr, or 8 hr to 24 hr, or 16 hr. In some embodiments, the mixing occurs with residence times of 0.1 min to 120 min, or 1 min to 60 min, or 10 min to 40 min, or 15 min to 30 min, or 25 min to 30 min. In some embodiments, the mixing occurs with a residence time of 35 minutes.
[0012] In various embodiments, the separation includes (a) cooling the reaction mixture to a temperature of 0°C to 50°C to form a cooled solution; (b) adding water to the cooled solution; and (c) precipitating the apremilast from the solution formed in step (b) to separate the apremilast. In various embodiments, the method further includes filtering the apremilast precipitated in step (c). In various embodiments, step (b) further includes adding crystalline apremilast to the cooled solution such that the precipitate from step (c) yields crystalline apremilast.
[0013] In various embodiments, the separation includes continuous crystallization using a mixed suspension mixed product rejection (MSMPR) crystallizer; parallel filtration; or a combination thereof.
[0014] Methods for separating apremilast from a reaction mixture comprising crude apremilast and DMSO are also provided, the methods comprising: (a) cooling the reaction mixture to a temperature of 0°C to 50°C to form a cooled solution; (b) adding water to the cooled solution; (c) precipitating apremilast from the solution formed in step (b) to form a precipitated apremilast; and (d) separating the precipitated apremilast. In various embodiments, the separation is performed by filtration. In various embodiments, step (b) further comprises adding crystalline apremilast to the cooled solution. In various embodiments, the precipitated apremilast is crystalline.
[0015] Methods for preparing apresto are also provided, the methods comprising (a) mixing (1) a first solution of 3-acetaminophen phthalic anhydride (compound A) contained in a first solvent and (2) a second solution of (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonylmethane)ethyl-1-amine (compound B) or a salt thereof contained in a second solvent to form apresto in a reaction mixture, wherein the mixing occurs in a continuous process apparatus; and (b) separating the apresto from the reaction mixture, wherein the separation comprises: (i) cooling the reaction mixture to a temperature of 0°C to 50°C; (ii) adding water to the cooled reaction mixture; (iii) precipitating apresto from the mixture of step (ii); and (iv) separating the precipitated apresto.
[0016] Methods for preparing crystalline apremilast are also provided, comprising: (a) mixing (1) a first solution of 3-acetaminophen phthalic anhydride (compound A) contained in a first solvent and (2) a second solution of (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonylurea)ethyl-1-amine (compound B) or a salt thereof contained in a second solvent to form apremilast in a reaction mixture, wherein the mixing occurs in a continuous process apparatus; and (b) separating the crystalline apremilast from the reaction mixture by continuous crystallization and parallel filtration. In various embodiments, the continuous crystallization includes the use of a mixed suspension mixture removal (MSMPR) crystallizer. Simple Explanation of the Diagram
[0017] [Figure 1] illustrates the flow chart of the continuous reaction method and continuous crystallization method of Apstec as disclosed in this paper.
[0018] [Figure 2] illustrates the continuous reaction method and manufacturing process of Apster as disclosed in this paper.
[0019] [Figure 3A] depicts the XRPD diagram of crystal form B of Apster as disclosed in this paper.
[0020] [Figure 3B] depicts a representative DVS diagram of Apster crystal form B. Implementation
[0021] The following discussion relates to various exemplary embodiments of the disclosed methods. However, the disclosed embodiments should not be construed as, or otherwise used to, limit the scope of this disclosure, including the requested items. Furthermore, those skilled in the art will understand that the following description has broad application, and the discussion of any embodiment is intended only as an example, and the scope of this disclosure, including the requested items, is not limited to that embodiment.
[0022] As used herein, the terms "including" and "comprise" are used in an open-ended manner and should therefore be interpreted as meaning "including, but not limited to...". As used herein, the term "about" when used in conjunction with a percentage or other numerical quantity means that percentage or other numerical quantity plus or minus 10%. For example, the term "about 80%" would cover 80% plus or minus 8%. Methods for synthesizing Apster
[0023] This article provides a method for obtaining apremilast. This article further provides a method for isolating and crystallizing apremilast.
[0024] In some embodiments, this disclosure provides methods for preparing aprestil, the methods comprising mixing (1) a first solution of 3-acetaminophen phthalic anhydride (compound A) or a salt thereof contained in a first solvent and (2) a second solution of (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonylmethane)ethyl-1-amine (compound B) or a salt thereof contained in a second solvent to form aprestil in a reaction mixture; and adding water to the reaction mixture to separate the aprestil. In some embodiments, the method for synthesizing aprestil is a continuous reaction method. In some embodiments, the method for synthesizing aprestil is a batch method.
[0025] In some embodiments, a continuous method (or continuous manufacturing (CM)) involves: a) continuously feeding input materials, b) continuously transforming materials within an internal process, and / or c) continuously removing output materials from the method. In some embodiments of a continuous method, two or more unit operations are directly connected, where a unit operation can be defined as a fundamental step in the method, involving physical changes or chemical transformations, such as, but not limited to, reactions, crystallization, distillation, and purification. In some embodiments, a continuous method can be applied to some or all of the unit operations.
[0026] Continuous methods can include a combination of manufacturing methods, some of which operate in batch mode while others are integrated and operate continuously. In some cases, the methods are integrated and operate continuously. In some embodiments, continuous reaction methods can incorporate buffer lines or buffer tanks to maintain a constant flow of material input and output in any mode of the continuous reaction methods described herein.
[0027] In some embodiments, the continuous reaction method comprises a series of chemical transformations, solvent changes, purification steps, etc., which may include integrating typical unit operations used in drug substance methods into a continuous process. In some embodiments, the integrated method may include a plug flow reactor (PFR) (where, for example, PFR design elements (e.g., size and configuration) allow for precise control of temperature, mixing, and reaction streams), a continuous stirred tank reactor (CSTR), homogeneous and heterogeneous extraction, continuous crystallization, and / or filtration. In some embodiments, starting materials may be coupled in a PFR to produce a crude product; the crude product may be purified by extraction and continuous crystallization. The crystal slurry may be filtered using units operated in an alternating manner, thereby allowing for continuous processing of the drug substance after crystallization. Starting materials / reactants
[0028] In the disclosed method, a solution of compound A or a salt thereof is mixed with a solution of compound B or a salt thereof to form Apres. In some cases, compound A may exist as a neutral substance (i.e., not as a salt). In some cases, compound A may exist as a salt. In some embodiments, the salt form of compound A may be an alkali metal or alkaline earth metal salt. Some particularly considered salt forms include, but are not limited to, calcium salts, magnesium salts, sodium salts, lithium salts, zinc salts, potassium salts, and iron salts. In some cases, compound B may exist as a free base (i.e., not as a salt) or as a neutral amine compound. In some cases, compound B may exist as a salt. In some embodiments, the salt form of compound B may be an acetate, benzenesulfonate, benzoate, bicarbonate, tartrate, bromide, calcium edetate, camphorsulfonate, carbonate, chloride, bromide, iodide, citrate, dihydrochloride, edetate, ethanedisulfonate, propionate lauryl sulfate, ethanesulfonate, fumarate, glucono-p-glucose, gluconate, glutamate, p-hydroxyacetaminophenarsine, hexylresorcinol, or hydrabamine. Hydroxynaphthalene, hydroxyethyl sulfonate, lactate, lactobionate, malate, maleate, amygdalinate, methanesulfonate, methyl sulfate, muscate, leucinate, naphthalene sulfonate, nitrate, pantothenate, phosphate / bisphosphate, polygalacturonate, salicylate, stearate, succinate, sulfate, tannate, tartrate, teoclate, triethyliodide, or dihydroxynaphthalene.
[0029] Compound A or its salts may be present in amounts of 10 mol equivalents or less based on compound B or its salts; for example, 9.5 mol equivalents, 9 mol equivalents, 8.5 mol equivalents, 8 mol equivalents, 7.5 mol equivalents, 7 mol equivalents, 6.5 mol equivalents, 6 mol equivalents, 5.5 mol equivalents, 5 mol equivalents, 4.5 mol equivalents, 4 mol equivalents, 3.5 mol equivalents, 3 mol equivalents, 2.5 mol equivalents, 2 mol equivalents, 1.5 mol equivalents, 1 mol equivalent, 0.5 mol equivalents, 0.4 mol equivalents, 0.3 mol equivalents, 0.2 mol equivalents, or 0.1 mol equivalents or less. Alternatively or additionally, in various embodiments, this disclosure provides a method for preparing apremilast, wherein compound A or a salt thereof is present in an amount of 0.1 mol equivalents or more based on compound B or a salt thereof, for example: 0.1 mol equivalents, 0.2 mol equivalents, 0.3 mol equivalents, 0.4 mol equivalents, 0.5 mol equivalents, 1 mol equivalent, 1.5 mol equivalents, 2 mol equivalents, 2.5 mol equivalents, 3 mol equivalents, 3.5 mol equivalents, 4 mol equivalents, 4.5 mol equivalents, 5 mol equivalents, 6 mol equivalents, 6.5 mol equivalents, 7 mol equivalents, 7.5 mol equivalents, 8 mol equivalents, 8.5 mol equivalents, 9 mol equivalents, 9.5 mol equivalents, or 10 mol equivalents or more. Therefore, in some embodiments, this disclosure provides a method for preparing apremilast, wherein compound A or a salt thereof may be present in an amount bounded by and including any combination of the aforementioned endpoints. In various embodiments, this disclosure provides a method for preparing apremilast, wherein compound A or a salt thereof is present in an amount of 0.4 to 1.5 molar equivalents based on compound B or a salt thereof. In some other embodiments, compound A or a salt thereof is present in an amount of 0.8 to 1.2 molar equivalents based on compound B or a salt thereof. In some embodiments, compound A or a salt thereof is present in an amount of 0.99 molar equivalents based on compound B or a salt thereof. solvent
[0030] A solution of compound A or a salt thereof is in a first solvent. A solution of compound B or a salt thereof is in a second solvent. In some embodiments, the first and second solvents are the same solvent. In some other embodiments, the first and second solvents are different solvents.
[0031] The first and / or second solvent system can be any solvent compatible with the condensation reaction to form aprestig. For example, the solvent can be selected based on its stability at the operating temperature of the disclosed method. Therefore, the solvent can be selected to have minimal or no thermal decomposition under the conditions of the method. The selected solvent can be chosen to avoid negative interactions with the reactants, intermediates, or products of the method, and to avoid reducing the yield of aprestig. The solvent can be selected to increase the solubility of the reactants (compound A and / or compound B), thereby improving the homogeneity of the reaction mixture. The solvent can promote accelerated reaction kinetics by facilitating safe operation at high temperatures. The solvent can also allow direct crystallization of aprestig from the reactant mixture (e.g., by adding water).
[0032] In various embodiments, the solvent is a polar aprotic solvent. As used herein, "polar aprotic solvent" means a solvent that, when measured at 20°C to 25°C (room temperature), lacks OH or NH bonds, has a dielectric constant (ε) greater than 6, and a dipole moment greater than 1.5 D. In some embodiments, the polar aprotic solvent has a dielectric constant of 10 to 60 at room temperature and 1 atmosphere. In some embodiments, the polar aprotic solvent has a dielectric constant of 20 to 55 at room temperature and 1 atmosphere; in some embodiments, the polar aprotic solvent has a dielectric constant of 30 to 50 at room temperature and 1 atmosphere.
[0033] The solvent can have any suitable boiling point, as long as it is stable under the conditions of the method (e.g., reaction temperature and pressure) such that it does not undergo significant thermal decomposition. In some embodiments, the polar aprotic solvent has a boiling point of about 40°C to about 200°C at 1 atmosphere. The solvent may have a boiling point of 40°C or higher, for example, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, 145°C, 150°C, 155°C, 160°C, 165°C, 170°C, 175°C, 180°C, 185°C, 190°C, 195°C, or 200°C or higher. Alternatively or additionally, in various embodiments, the solvent may have a boiling point of 200°C or lower, such as 195°C, 190°C, 185°C, 180°C, 175°C, 170°C, 165°C, 160°C, 155°C, 150°C, 145°C, 135°C, 130°C, 125°C, 120°C, 115°C, 110°C, 110°C, 105°C, 100°C, 95°C, 90°C, 85°C, 80°C, 75°C, 75°C, 70°C, 65°C, 60°C, 55°C, 50°C, or 45°C or lower. Therefore, in some embodiments, the boiling point of the selected solvent may include, but is not limited to, any combination of the aforementioned endpoints.
[0034] In some embodiments, the polar aprotic solvent has 10% or less water by weight, for example 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% or less. In some specific embodiments, the polar aprotic solvent is anhydrous.
[0035] Polar aprotic solvents specifically considered for use in the disclosed methods include acetonitrile, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMAC), N-methyl-2-pyrrolidone (NMP), hexamethylphosphatidylamine (HMPA), N,N′-dimethylpropylideneurea (DMPU), cyclobutane, dihydro-L-glucosidone, 1,3-dimethyl-2-imidazolinone (DMI), or combinations thereof. In some embodiments, the polar aprotic solvent includes dimethyl sulfoxide (DMSO). The use of polar aprotic solvents (such as DMSO) as reaction solvents has been shown to provide the following improvements: 1) accelerated reaction kinetics via safe operation at high temperatures; 2) increased solubility of the reaction components, resulting in homogeneous reaction solutions; and 3) direct crystallization of apremilast from the crude reaction stream, eliminating the need for time-consuming and resource-intensive downstream processing steps. Other additives used in the disclosed method
[0036] In some embodiments, the disclosed method can be carried out in the presence of an acid. In some embodiments, the acid is an alkyl sulfonic acid, an aryl sulfonic acid, an alkyl carboxylic acid, or an aryl carboxylic acid. In some embodiments, the acid is selected from the group consisting of acetic acid, methanesulfonic acid, toluenesulfonic acid, trifluoroacetic acid, trichloroacetic acid, dichloroacetic acid, chloroacetic acid, benzenesulfonic acid, trifluoromethanesulfonic acid, ethyl sulfonic acid, formic acid, propionic acid, benzoic acid, salicylic acid, and oxalic acid. In some embodiments, the acid comprises acetic acid.
[0037] The acid can be present in amounts of 20 volume equivalents or less based on compound B or its salts, for example, 20 volume equivalents, 19.5 volume equivalents, 19 volume equivalents, 18.5 volume equivalents, 18 volume equivalents, 17.5 volume equivalents, 17 volume equivalents, 16.5 volume equivalents, 16 volume equivalents, 15.5 volume equivalents, 14 volume equivalents, 13.5 volume equivalents, 13 volume equivalents, 12.5 volume equivalents, 12 volume equivalents, 11.5 volume equivalents, 11 volume equivalents, 10.5 volume equivalents, 1 0 volume equivalent, 9.5 volume equivalent, 9 volume equivalent, 8.5 volume equivalent, 8 volume equivalent, 7.5 volume equivalent, 7 volume equivalent, 6.5 volume equivalent, 6 volume equivalent, 5.5 volume equivalent, 5 volume equivalent, 4.5 volume equivalent, 4 volume equivalent, 3.5 volume equivalent, 3 volume equivalent, 2.5 volume equivalent, 2 volume equivalent, 1.5 volume equivalent, 1 volume equivalent, 0.5 volume equivalent, 0.4 volume equivalent, 0.3 volume equivalent, 0.2 volume equivalent, or 0.1 volume equivalent. Alternatively or additionally, in various embodiments, the acid is present in 0.01 volume equivalents or more based on compound B or its salts, for example, 0.1, 0.2, 0.3, 0.4, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 6.5, 7, 7.5, and 8 volume equivalents based on compound B or its salts. 8.5 volume equivalents, 9 volume equivalents, 9.5 volume equivalents, 10 volume equivalents, 10.5 volume equivalents, 11 volume equivalents, 11.5 volume equivalents, 12 volume equivalents, 12.5 volume equivalents, 13 volume equivalents, 13.5 volume equivalents, 14 volume equivalents, 14.5 volume equivalents, 15 volume equivalents, 15.5 volume equivalents, 16 volume equivalents, 16.5 volume equivalents, 17 volume equivalents, 17.5 volume equivalents, 18 volume equivalents, 18.5 volume equivalents, 19 volume equivalents, 19.5 volume equivalents, or 20 volume equivalents. Therefore, in some embodiments, the acid can be present in volume equivalents based on compound B or its salts, including any combination of the aforementioned endpoints. For example, the acid is present in volume equivalents from 0.01 to 20 volume equivalents based on compound B or its salts. In some cases, the acid is present in volume equivalents from 0.1 to 10 volume equivalents based on compound B or its salts. In some cases, the acid is present in a volume equivalent of 0.5 to 3 based on compound B or its salt. In other cases, the acid is present in a volume equivalent of 1 to 2.5 based on compound B or its salt.
[0038] The acid can be present in amounts of 20 mol equivalents or less based on compound B or its salts, for example, 20 mol equivalents, 19.5 mol equivalents, 19 mol equivalents, 18.5 mol equivalents, 18 mol equivalents, 17.5 mol equivalents, 17 mol equivalents, 16.5 mol equivalents, 16 mol equivalents, 15.5 mol equivalents, 14 mol equivalents, 13.5 mol equivalents, 13 mol equivalents, 12.5 mol equivalents, 12 mol equivalents, 11.5 mol equivalents, 11 mol equivalents, 10.5 mol equivalents, 1 0 mol equivalent, 9.5 mol equivalent, 9 mol equivalent, 8.5 mol equivalent, 8 mol equivalent, 7.5 mol equivalent, 7 mol equivalent, 6.5 mol equivalent, 6 mol equivalent, 5.5 mol equivalent, 5 mol equivalent, 4.5 mol equivalent, 4 mol equivalent, 3.5 mol equivalent, 3 mol equivalent, 2.5 mol equivalent, 2 mol equivalent, 1.5 mol equivalent, 1 mol equivalent, 0.5 mol equivalent, 0.4 mol equivalent, 0.3 mol equivalent, 0.2 mol equivalent, or 0.1 mol equivalent. Alternatively or additionally, in various embodiments, the acid is present in amounts of 0.01 mol equivalents or more based on compound B or its salts, for example, 0.1 mol equivalents, 0.2 mol equivalents, 0.3 mol equivalents, 0.4 mol equivalents, 0.5 mol equivalents, 1 mol equivalent, 1.5 mol equivalents, 2 mol equivalents, 2.5 mol equivalents, 3 mol equivalents, 3.5 mol equivalents, 4 mol equivalents, 4.5 mol equivalents, 5 mol equivalents, 6 mol equivalents, 6.5 mol equivalents, 7 mol equivalents, 7.5 mol equivalents, and 8 mol equivalents based on compound B or its salts. The amounts are 8.5 mol equivalents, 9 mol equivalents, 9.5 mol equivalents, 10 mol equivalents, 10.5 mol equivalents, 11 mol equivalents, 11.5 mol equivalents, 12 mol equivalents, 12.5 mol equivalents, 13 mol equivalents, 13.5 mol equivalents, 14 mol equivalents, 14.5 mol equivalents, 15 mol equivalents, 15.5 mol equivalents, 16 mol equivalents, 16.5 mol equivalents, 17 mol equivalents, 17.5 mol equivalents, 18 mol equivalents, 18.5 mol equivalents, 19 mol equivalents, 19.5 mol equivalents, or 20 mol equivalents. Therefore, in some embodiments, the acid can be present in mol equivalents based on compound B or its salts, including any combination of the aforementioned endpoints. For example, the acid is present in amounts from 0.01 to 20 mol equivalents based on compound B or its salts. In some cases, the acid is present in amounts of 0.1 to 15 mol equivalents based on compound B or its salts. In some cases, the acid is present in amounts of 5 to 12 mol equivalents based on compound B or its salts. In some cases, the acid is present in amounts of 11 to 12 mol equivalents based on compound B or its salts.
[0039] In some embodiments, the mixing is carried out in the presence of up to 1.5 mol equivalents of water based on compound B or a salt thereof; in some embodiments, up to 1.25 mol equivalents of water based on compound B or a salt thereof are present. In some embodiments, up to 1 mol equivalent of water based on compound B or a salt thereof are present. In some embodiments, up to 0.75 mol equivalents of water based on compound B or a salt thereof are present. In some embodiments, water is present at 0.5 mol equivalents based on compound B or a salt thereof. In various embodiments, water is present at 0.25 mol equivalents based on compound B or a salt thereof. In some embodiments, water is not present. temperature
[0040] The methods for preparing aprestil, as disclosed herein, can occur within a certain temperature range. The disclosed methods can be carried out at elevated temperatures compared to previous aprestil syntheses, thus providing shorter reaction times; for example, the reaction can occur within hours or minutes instead of days. Therefore, the synthesis of aprestil as described herein is feasible, yields suitable amounts, and is particularly easy to scale up industrially, resulting in cost savings and reduced solvent waste associated with these methods. Therefore, in some embodiments, this disclosure provides a method for preparing aprestil in which the mixing of compounds A and B, as discussed above, can be carried out at temperatures from 20°C to 200°C. In some embodiments, the mixing is carried out at temperatures from 70°C to solvent reflux. In some embodiments, the mixing is carried out at temperatures from 50°C to 200°C. In some embodiments, the mixing is carried out at temperatures from 70°C to 190°C. In various embodiments, the mixing is carried out at temperatures from 130°C to 135°C. In various embodiments, mixing is carried out at a temperature of 20°C or higher, for example, 25°C, 30°C, 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, 145°C, 150°C, 155°C, 160°C, 165°C, 170°C, 175°C, 180°C, 185°C, 190°C, 195°C, 200°C, 205°C, or 210°C or higher. Alternatively or additionally, in various embodiments, this disclosure provides a method for preparing apremilast, wherein mixing is carried out at a temperature of 210°C or lower, for example, 205°C, 200°C, 195°C, 190°C, 185°C, 180°C, 175°C, 170°C, 165°C, 160°C, 155°C, 150°C, 145°C. C, 135°C, 130°C, 125°C, 120°C, 115°C, 110°C, 110°C, 105°C, 100°C, 95°C, 90°C, 85°C, 80°C, 75°C, 75°C, 70°C, 65°C, 60°C, 55°C, 50°C, 45°C, 40°C, 35°C, 30°C or lower. Therefore, in some embodiments, this disclosure provides a method for preparing Apster, wherein mixing is carried out at temperatures bounded by and including any combination of the aforementioned endpoints. reaction time
[0041] The methods for preparing apremilast disclosed herein can occur within a certain reaction time range and provide commercially relevant reaction times. In some embodiments, the mixing of compound A and compound B, as discussed above, occurs with an average reaction time of 0.1 minutes to 48 hours. In some embodiments, the mixing occurs with an average reaction time of 4 hours to 36 hours. In some embodiments, the mixing occurs with an average reaction time of 8 to 24 hours. In some embodiments, the mixing occurs with an average reaction time of 16 hours. In various embodiments, the mixing occurs for a duration of 5 minutes to 16 hours, for example, 15, 30, or 45 minutes or longer. In some cases, the mixture lasts for 16 hours or less, for example, 15.5 hours or less, 15 hours or less, 14.5 hours or less, 14 hours or less, 13.5 hours or less, 13 hours or less, 12.5 hours or less, 12 hours or less, 11.5 hours or less, 11 hours or less, 10.5 hours or less, 10 hours or less, 9.5 hours or less, 9 hours or less, 8.5 hours or less, 8 hours or less, 7.5 hours or less, 7 hours or less, 6.5 hours or less, 6 hours or less, 5.5 hours or less, 5 hours or less, 4.5 hours or less, 4 hours or less, 3.5 hours or less, 3 hours or less, 2.5 hours or less, 2 hours or less, 1.5 hours or less, or 1 hour or less. In various implementations, the mixing process lasts from 1 to 4 hours. Duration of stay
[0042] In some embodiments, mixing occurs as a continuous reaction process. For example, the reaction can occur in a plug flow reactor (PFR). A plug flow reactor can be used in continuous reaction methods where the concentrations and temperatures of reactants (such as compound A or its salt in a first solvent and compound B or its salt in a second solvent) are consistent. A plug flow reactor has a fixed residence time (τ). The reaction mixture flowing through the PFR can be considered as a series of coherent "plugs" flowing through the reactor, each plug having a consistent composition and traveling only in the axial direction of the reactor. As the plugs flow through the PFR, the reaction mixture mixes in the radial direction. The average residence time (τ) in the PFR is the average time the reactants spend in the PFR. Residence time refers to the time that would otherwise be considered "reaction time" in conventional or batch processes.
[0043] The method for preparing apremilast disclosed herein can occur within a certain residence time range. The residence time can be 120 minutes or less; for example: 115 minutes; 110 minutes; 105 minutes; 100 minutes; 95 minutes; 90 minutes; 85 minutes; 80 minutes; 75 minutes; 70 minutes; 65 minutes; 60 minutes; 55 minutes; 50 minutes; 45 minutes; 40 minutes; 35 minutes; 30 minutes; 25 minutes; 20 minutes; 15 minutes; 10 minutes; 5 minutes; 1 minute; 0.9 minutes; 0.8 minutes; 0.7 minutes; 0.6 minutes; 0.5 minutes; 0.4 minutes; 0.3 minutes; 0.2 minutes; or 0.1 minutes or less. Alternatively or additionally, in various embodiments, the dwell time may be 0.1 minutes or longer, for example 0.1 minutes; 0.2 minutes; 0.3 minutes; 0.4 minutes; 0.5 minutes; 0.6 minutes; 0.7 minutes; 0.8 minutes; 0.9 minutes; 1 minute; 1.5 minutes; 2 minutes; 2.5 minutes; 3 minutes; 3.5 minutes; 4 minutes; 4.5 minutes; 5 minutes; 10 minutes; 15 minutes; 20 minutes; 25 minutes; 30 minutes; 35 minutes; 40 minutes; 45 minutes; 50 minutes; 55 minutes; 60 minutes; 65 minutes; 70 minutes; 75 minutes; 80 minutes; 85 minutes; 90 minutes; 95 minutes; 100 minutes; 110 minutes; 115 minutes; or 120 minutes or longer. Therefore, in some embodiments, dwell times are mixed, defined by and including any combination of the aforementioned endpoints. In various implementations, mixing occurs at the following residence times: 0.1 to 120 minutes, or 1 minute to 60 minutes; or 10 minutes to 40 minutes; or 15 minutes to 30 minutes; or 25 minutes to 30 minutes, or 25 minutes to 35 minutes. Separate Apster
[0044] Comparative methods for preparing aprestig from compounds A and B are carried out in tetrahydrofuran (see, for example, Example 9 in the Examples section below for a typical procedure using tetrahydrofuran). This method requires a long reaction time (at least 16 h at 70°C to 75°C). Separation of crude aprestig from the THF reaction mixture requires a series of aqueous treatment steps, followed by distillation, and finally crystallization from a solvent mixture such as isopropyl acetate and methyl tributyl ether. In view of the foregoing, this disclosure provides a method for both the direct separation of aprestig from the reaction mixture and the production of crystalline aprestig.
[0045] Therefore, in some embodiments, this disclosure provides a method for preparing apremilast, which further includes adding water to the reaction mixture to separate apremilast. In some embodiments, separating apremilast from the reaction mixture includes: (a) cooling the reaction mixture to a temperature of 0°C to 50°C to form a cooled solution; (b) adding water to the cooled solution; and (c) precipitating apremilast from the solution formed in step (b) to separate apremilast. In some embodiments, the method further includes filtering the apremilast precipitate from step (c). In some embodiments, step (b) further includes adding crystallized apremilast to the cooled solution such that the precipitate from step (c) produces crystallized apremilast. In some embodiments, the separation includes continuous crystallization using a mixed suspension mixed product removal (MSMPR) crystallizer, parallel filtration, or a combination thereof. Cool the reaction mixture
[0046] The cooling in step (b) is performed at 0°C or higher, for example, 5°C, 10°C, 15°C, 20°C, 25°C, 30°C, 35°C, 40°C, or 45°C or higher. Alternatively or additionally, in various embodiments, cooling is performed at 50°C or lower, for example, 45°C, 40°C, 35°C, 30°C, 25°C, 20°C, 15°C, 10°C, or lower. Thus, in some embodiments, the cooling of the reaction mixture is performed at a temperature bounded by and including any combination of the aforementioned endpoints. In some cases, cooling comprises cooling the mixture to room temperature (20°C to 25°C).
[0047] This paper unexpectedly discovers and discloses several methodological improvements for implementing DMSO as a reaction solvent, including facilitating the direct crystallization of crude apremilast from the reaction mixture (or reaction stream), thereby eliminating the need for time-consuming and resource-intensive downstream processing steps. Additionally, inoculating the reaction mixture with crystalline apremilast allows for precipitation of the crystalline apremilast. Therefore, in some embodiments, this disclosure provides a method for separating apremilast from a reaction mixture comprising crude apremilast and DMSO, the method comprising (a) cooling the reaction mixture to a temperature of 0°C to 50°C to form a cooled solution; (b) adding water to the cooled solution; (c) precipitating apremilast from the solution formed in step (b) to form a precipitated apremilast; and (d) separating the precipitated apremilast. In some embodiments, step (b) further comprises adding crystalline apremilast to the cooled solution, such that the precipitated apremilast is crystalline.
[0048] The crystalline apres formed in the disclosed method can be in any crystalline form. Various crystalline apres forms are described in detail in PCT Publication No. WO 2009 / 120167, the disclosure of which is incorporated herein by reference in its entirety. In various embodiments, the crystalline apres formed by the method disclosed herein can be of form A, form B, or form F. In some cases, the crystalline apres is of form B. Form B can be characterized by X-ray powder diffraction analysis. A representative XRPD pattern of form B is provided in Figure 3. In some embodiments, form B is characterized by XRPD peaks located at approximately one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve of the following approximate positions: 10.1, 12.4, 13.5, 15.7, 16.3, 18.1, 20.7, 22.5, 24.7, 26.2, 26.9, 29.1 degrees 2θ. In some embodiments, form B is characterized by an XRPD spectrum that matches the spectrum shown in Figure 3. In some embodiments, form B can be characterized by thermal analysis. A representative DSC plot of form B is shown in Figure 3. In some embodiments, form B is characterized by a DSC plot including an endothermic event with an initial temperature of about 154°C. A representative TGA plot of form B is shown in Figure 3. In some embodiments, form B is characterized by a TGA plot showing a mass loss of less than about 1% (e.g., about 0.25%) of the total mass of the sample after heating the sample from about 25°C to about 140°C. In some embodiments, form B does not contain real mass of water or other solvents in the crystal lattice. In some embodiments, form B is anhydrous. In some embodiments, form B is non-solventized. In some embodiments, form B can be characterized by moisture adsorption analysis. A representative moisture adsorption isotherm plot is shown in Figure 3b. In some embodiments, form B exhibits a mass change of less than about 1% (e.g., about 0.6%) of the initial sample mass when the RH increases from about 0% to about 95% RH. In some embodiments, there is a mass loss following adsorption when the RH drops back to about 0% RH. In some embodiments, form B is substantially non-hygroscopic. In some embodiments, the XRPD pattern of form B material remains substantially unchanged after adsorption / desorption analysis. In some embodiments, form B is stable with respect to humidity.
[0049] The continuous reaction method disclosed herein is, to some extent, an efficient method for producing apremilast because the reactants (compound A and compound B) are readily soluble in polar aprotic solvents (such as DMSO), thus providing a reaction stream suitable for PFR (Polymerized Reaction Flow). The reaction stream enters the PFR, and suitable residence time and temperature within the PFR promote the reaction. The reaction stream containing crude apremilast can then undergo continuous crystallization, including the use of a Mixed Suspension Mixed Product Removal (MSMPR) crystallizer. This continuous reaction method then allows for the separation of crystallized apremilast without intermediate separation of crude apremilast or multiple solvent washes, reducing reaction costs and production time.
[0050] In some embodiments, a reaction stream containing crude apres and water is mixed with crystalline apres in an MSMPR for seeded crystallization to provide crystalline apres. Therefore, in some embodiments, this disclosure provides a method for preparing apres, comprising reacting compound A or a salt thereof with compound B or a salt thereof as discussed above, such that the reaction occurs in a continuous reaction apparatus, wherein crude apres is formed in the reaction mixture; and the method further comprises separating apres from the reaction mixture. In various cases, separation comprises cooling the reaction mixture to a temperature of 0°C to 50°C; adding water to the cooled reaction mixture; precipitating apres from the cooled reaction mixture; and separating the precipitated apres.
[0051] In some embodiments, this disclosure provides methods for preparing crystalline apremilast, the methods comprising: a) mixing (1) a first solution of compound A or a salt thereof contained in a first solvent and (2) a second solution of compound B or a salt thereof contained in a second solvent to form apremilast in a reaction mixture, wherein the mixing is carried out in a continuous reaction process apparatus; and (b) separating the crystalline apremilast from the reaction mixture by continuous crystallization and parallel filtration. In various cases, the separation of crystalline apremilast may include using a mixed suspension mixture removal (MSMPR) crystallizer. Implementation 1. A method for preparing apremilast, the method comprising: A first solution of (1) 3-acetaminophthalic anhydride (compound A) or a salt thereof contained in a first solvent and a second solution of (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonylmethane)ethyl-1-amine (compound B) or a salt thereof contained in a second solvent are mixed to form Apster in the reaction mixture; and Water is added to the reaction mixture to separate the apster. 2. The method as described in Embodiment 1, wherein compound A or a salt thereof is present in an amount of 0.4 to 1.5 molar equivalents based on compound B or a salt thereof. 3. The method as described in Embodiment 2, wherein compound A or a salt thereof is present in an amount of 0.8 to 1.2 molar equivalents based on compound B or a salt thereof. 4. The method as described in Embodiment 3, wherein compound A or a salt thereof is present in an amount of 0.99 molar equivalents based on compound B or a salt thereof. 5. The method as described in any one of embodiments 1-4, wherein compound A is not in salt form. 6. The method as described in any one of embodiments 1-5, wherein the first solvent and the second solvent are the same solvent. 7. The method as described in any one of embodiments 1-6, wherein the first solvent and the second solvent are different solvents. 8. The method as described in any one of embodiments 1-7, wherein the first solvent is a polar aprotic solvent. 9. The method as described in any one of embodiments 1-8, wherein the second solvent is a polar aprotic solvent. 10. The method as described in Embodiment 8 or 9, wherein the polar aprotic solvent has a boiling point of about 40°C to about 200°C at 1 atmosphere. 11. The method as described in any one of embodiments 8-10, wherein the polar aprotic solvent has 0-10% water by weight. 12. The method as described in any one of embodiments 8-10, wherein the polar aprotic solvent is anhydrous. 13. The method as described in any one of embodiments 8-12, wherein the polar aprotic solvent has a dielectric constant of 10 to 50 at room temperature and 1 atmosphere. 14. The method as described in any one of embodiments 8-13, wherein the polar aprotic solvent is acetonitrile, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMAC), N-methyl-2-pyrrolidone (NMP), hexamethylphosphonamide (HMPA), N,N′-dimethylpropylideneurea (DMPU), cyclobutane, dihydro-L-glucosidone, 1,3-dimethyl-2-imidazolinone (DMI), or a combination thereof. 15. The method as described in any one of embodiments 8-14, wherein the polar aprotic solvent comprises dimethyl sulfoxide (DMSO). 16. The method as described in any one of embodiments 8-15, wherein the mixing is carried out in the presence of an acid. 17. The method as described in Embodiment 16, wherein the acid is an alkyl sulfonic acid, aryl sulfonic acid, alkyl carboxylic acid, or aryl carboxylic acid. 18. The method as described in embodiment 16 or 17, wherein the acid is selected from the group consisting of: acetic acid, methanesulfonic acid, toluenesulfonic acid, trifluoroacetic acid, trichloroacetic acid, dichloroacetic acid, chloroacetic acid, benzenesulfonic acid, trifluoromethanesulfonic acid, ethylsulfonic acid, formic acid, propionic acid, benzoic acid, salicylic acid, and oxalic acid. 19. The method as described in any one of embodiments 16-18, wherein the acid comprises acetic acid. 20. The method as described in any one of embodiments 16-19, wherein the acid is present in a volume equivalent of 0.01 to 20 based on compound B or a salt thereof. 21. The method as described in any one of embodiments 16-20, wherein the acid is present in a volume equivalent of 0.1 to 10 based on compound B or a salt thereof. 22. The method as described in any one of embodiments 16-21, wherein the acid is present in a volume equivalent of 0.5 to 3 based on compound B or a salt thereof. 23. The method as described in embodiment 22, wherein the acid is present in a volume equivalent of 1 to 2.5 based on compound B or a salt thereof. 24. The method as described in any one of embodiments 1-23, wherein the mixing is carried out in the presence of up to 1.5 molar equivalents of water based on compound B or a salt thereof. 25. The method as described in any one of embodiments 1-24, wherein the mixing is carried out in the absence of water. 26. The method as described in embodiment 24, wherein the water is present in an amount of 0.5 molar equivalents based on compound B or a salt thereof. 27. The method as described in any one of embodiments 1-26, wherein the mixing is carried out at a temperature of 20°C to 200°C. 28. The method as described in Embodiment 27, wherein the mixing is carried out at a temperature of 70°C to the solvent reflux temperature. 29. The method as described in Embodiment 27, wherein the mixing is carried out at a temperature of 50°C to 200°C. 30. The method as described in Embodiment 29, wherein the mixing is carried out at a temperature of 70°C to 190°C. 31. The method as described in embodiment 30, wherein the mixing is carried out at a temperature of 130°C to 135°C. 32. The method as described in any one of embodiments 1-31, wherein the mixing occurs over a reaction time of 0.1 minutes to 48 hours. 33. The method as described in any one of embodiments 1-32, wherein the mixing occurs over a reaction time of 4 to 36 hours. 34. The method as described in any one of embodiments 1-33, wherein the mixing occurs over a reaction time of 8 to 24 hours. 35. The method as described in any one of embodiments 1-34, wherein the mixing occurs over a reaction time of 16 hours. 36. The method as described in any one of embodiments 1-31, wherein the mixing occurs with a residence time of 0.1 to 120 minutes. 37. The method as described in embodiment 36, wherein the mixing occurs with a residence time of 1 minute to 60 minutes. 38. The method as described in embodiment 37, wherein the mixing occurs with a residence time of 10 to 40 minutes. 39. The method as described in embodiment 38, wherein the mixing occurs with a residence time of 15 to 30 minutes. 40. The method as described in embodiment 39, wherein the mixing occurs for a residence time of 25 to 30 minutes. 41. The method as described in any one of embodiments 1-31 and 36-40, wherein the mixing occurs in a plug flow reactor. 42. The method as described in any one of embodiments 1-41, wherein the separation comprises: (a) Cooling the reaction mixture to a temperature of 0°C to 50°C to form a cooled solution; (b) Add water to the cooled solution; and (c) Precipitate the aprestin from the solution formed in step (b) to separate the aprestin. 43. The method as described in embodiment 42, further comprising apström filtration of the precipitate from step (c). 44. The method as described in embodiment 42, wherein step (b) further comprises adding crystalline apremilast to the cooled solution such that the precipitate of step (c) produces crystalline apremilast. 45. The method as described in any one of embodiments 1-41, wherein the separation comprises continuous crystallization using a mixed suspension mixture removal (MSMPR) crystallizer; parallel filtration; or a combination thereof. 46. A method for separating apremilast from a reaction mixture comprising crude apremilast and DMSO, the method comprising: (a) Cooling the reaction mixture to a temperature of 0°C to 50°C to form a cooled solution; (b) Add water to the cooled solution; (c) Precipitate Aprestin from the solution formed in step (b) to form a precipitated Aprestin; and (d) Separate the precipitate from the aprepitant. 47. The method as described in embodiment 46, wherein the separation is performed by filtration. 48. The method as described in embodiment 46 or 47, wherein step (b) further comprises adding crystalline apremilast to the cooled solution. 49. The method as described in any one of embodiments 46-48, wherein the precipitate is an Apster-based crystal. 50. A method for preparing apremilast, the method comprising: (a) A first solution of 3-acetaminophen phthalic anhydride (compound A) contained in a first solvent and a second solution of (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonylmethane)ethyl-1-amine (compound B) or a salt thereof contained in a second solvent are mixed to form Apres in the reaction mixture, wherein the mixing occurs in a continuous process apparatus; and (b) Separating the apremilast from the reaction mixture, wherein the separation comprises: (i) Cool the reaction mixture to a temperature of 0°C to 50°C; (ii) Add water to the cooled reaction mixture; (iii) Precipitate Apsir from the mixture of step (ii); and (iv) Separate the precipitate from the aprepitant. 51. A method for preparing crystalline apremilast, the method comprising: (s) Mixing (1) a first solution of 3-acetaminophen phthalic anhydride (compound A) contained in a first solvent and (2) a second solution of (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonylurea)ethyl-1-amine (compound B) or a salt thereof contained in a second solvent to form Apres in the reaction mixture, wherein the mixing occurs in a continuous process apparatus; and (b) Crystallized Apster is separated from the reaction mixture by continuous crystallization and parallel filtration. 52. The method as described in embodiment 46, wherein the continuous crystallization includes using a mixed suspension mixed product removal (MSMPR) crystallizer.
[0052] The embodiments provided herein can be more fully understood by referring to the following examples. These examples are intended to illustrate the pharmaceutical compositions and dosage forms provided herein, but are not intended to limit the scope in any way. [] [Example] []
[0053] The following examples further illustrate the disclosed methods, but should not, of course, be construed as limiting their scope in any way. Example 1
[0054] This article provides an example of a continuous reaction method for the preparation of aprestil and subsequent continuous crystallization of aprestil, as generally depicted in Figure 1. In a first feed tank, 3-acetaminophen phthalic anhydride (compound A, 1.059 kg, 0.99 equivalents) is dissolved in DMSO (14.23 L, 10 L / kg). In a second feed tank, (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonylurea)ethyl-1-amine (compound B, 1.425 kg, 1.0 equivalents) is dissolved in DMSO (1.43 L, 1.0 L / kg), and acetic acid (3.56 L, 2.5 L / kg) is added to the solution in the second feed tank. The contents of the first and second feed tanks are pumped into a plug flow reactor at rates of 9.96 mL / min and 4.0 mL / min, respectively. The reaction stream was mixed and heated at 130°C for an average residence time (τ) of 25 minutes to form crude aprestig. To separate the aprestig, the reaction stream was sequentially passed through a series of three MSMPR vessels. In the first of the three MSMPR vessels, water and the reaction stream were simultaneously added to a seed bed containing DMSO, water, and crystalline aprestig seeds to form a mixture containing 30% water, while the temperature of the reaction stream was maintained at 25°C with agitation. The resulting slurry was then pumped into a second MSMPR vessel, and water was added to obtain a mixture containing 40% water. The slurry was further transferred to a third MSMPR for additional aging. The average residence time in each of the three MSMPRs was 60 minutes. The combined aprestig product was washed with water and ethanol and dried. In a continuous reaction method, the reactants were added simultaneously and the product was discharged from the process system.
[0055] In the alternative method of Example 1, the continuous reaction method includes multiple discrete residence times, in which the material properties of the system reach a steady state and remain constant over time, making the method consistent in terms of product output. Example 2
[0056] In another example of a continuous reaction method for the preparation of aprestil and subsequent continuous crystallization of aprestil, compound A (222.9 g / 0.99 equivalent) is dissolved in DMSO (3.0 L, 10 L / kg compound B) in a first feed tank, and compound B (300 g, 1.00 equivalent) is dissolved in DMSO (0.3 L, 1 L / kg) in a second feed tank. Acetic acid (0.75 L, 2.5 L / kg) and water (10.2 mL, 0.034 L / kg) are added to the second feed tank. The contents of the first and second feed tanks are pumped into a plug flow reactor, where the reaction streams are axially mixed and heated at 130°C for an average residence time (τ) of 25 minutes to form crude aprestil. The crude reaction stream is collected and stored. Aprestil is then separated from the stored reaction stream. As described above, a first volume of stored reaction stream was crystallized using MSMPR, and a second volume was crystallized by batch crystallization, wherein water (antisolvent) was added directly to the stored reaction stream and the apremilast precipitate was subsequently filtered, washed, and dried. The yield of apremilast was 98%. Example 3
[0057] Aprestil was prepared by batch crystallization using a continuous reaction method and a batch crystallization method, as outlined in Figure 2. In a first feed tank, compound A (440 g, 0.99 equivalents) was dissolved in DMSO (6 L, 10 L / kg compound B), and in a second feed tank, compound B (594 g, 1 equivalent) was dissolved in DMSO (0.6 L, 1 L / kg). Acetic acid (1.5 L, 2.5 L / kg) and water (0.2 L, 0.034 L / kg) were added to the second feed tank. The contents of the first and second feed tanks were pumped into a plug flow reactor, where the reaction streams were axially mixed and heated at 130°C for an average residence time (τ) of 20 minutes to form crude aprestil. The crude reaction stream was collected and then apremilast was separated from the reaction stream, so that apremilast was produced at a rate of 43 g / hr. Apremilast was crystallized by batch crystallization, in which water (antisolvent) was added directly to the stored reaction stream and the apremilast precipitate was subsequently filtered, washed and dried. Example 4
[0058] Further experiments were conducted to achieve continuous production of apremilast at various temperatures, flow rates, volumes, and residence times. Solutions of compound A (0.99 equivalents, 0.35 mol / L) and compound B (1.0 equivalents, 0.88 mol / L) with flow rates of 1.57 mmol / min and 1.58 mmol / min, respectively, were reacted in a PFR containing a volume of 125.61 mL and a residence time of 20 min, with the reaction stream heated at 130°C. This resulted in the production of apremilast at a daily flux of approximately 43.33 g / hr and approximately 1.04 kg / 24 hr. Example 5
[0059] Solutions of compound A (0.99 equivalent, 0.35 mol / L) and compound B (1.0 equivalent, 0.88 mol / L) with flow rates of 1.31 mmol / min and 1.32 mmol / min, respectively, were reacted in a PFR containing a volume of 130.84 mL and a residence time of 25 min, wherein the reaction stream was heated at a temperature of 130°C, which resulted in the production of apremilast at a daily flux of approximately 36.11 g / hr and approximately 0.87 kg / 24 hr. Example 6
[0060] Aprestil was produced using a batch process (where all reactants were added before the start of the process and drained at the end), with DMF used as the polar aprotic solvent. Compound B (5.0 g, 1.0 equivalent), water (0.17 mL, 0.034 mL / g), and DMF (30 mL, 6 mL / g) were added to a 100 mL EasyMax reactor to obtain a clear solution. The temperature was set to 20°C, and acetic acid (13 mL, 2.5 mL / g) was slowly added using a syringe. Then, compound A (3.8 g, 0.99 equivalent) was added to the reactor, and the reaction mixture was heated to 70°C. The reaction was monitored by UPLC and completed within 18 hours. The yield of crude aprestil was 75%. Example 7 Aprestil was produced by a batch process using DMSO as a polar aprotic solvent. A 100 mL EasyMax reactor was equipped with a temperature probe, reflux condenser, nitrogen inlet, and EasySampler probe; and compound B (6.02 g, 1 equivalent); anhydrous DMSO (36 mL, 6 mL / g); and water (0.20 mL, 0.034 mL / g) were added sequentially. After the addition of DMSO (to completely dissolve compound B), a clear solution was obtained. The reaction mixture was cooled to 20°C, and then acetic acid (15 mL, 2.5 mL / g) was slowly added via syringe. Solid compound A (4.48 g, 0.99 equivalent) was added, and the temperature was ramped up to 70°C over 1 hour, and then the reaction was cooled to 35°C. After 10 h, the reaction was run to completion. Example 8
[0061] Aprestil can be prepared by batch crystallization. Water (6.00 mL, 1.0 mL / g) was added dropwise to a reaction mixture containing crude aprestil (which may be a product of batch or continuous production methods) via a syringe pump at 35°C for 15 minutes, and the mixture was stirred at 35°C for 20 minutes. 50 mg of aprestil seed crystals (0.5 wt%) were added to the solution. The solution immediately became turbid. The slurry was aged at 35°C for 1 hour, and then 3 volumes of water (18 mL, 3.0 mL / g) were added via a syringe pump over 1 hour. The turbid solution was cooled to 15°C over 90 minutes and then stirred overnight at 15°C. The slurry was filtered, washed with water (25 mL), and dried overnight under nitrogen purging. Crystalline apremilast (9.47 g) (99.57% (according to qnmr); 99.86 LCAP purity) was obtained and subjected to 1H NMR (1h nmr (500 mhz, CD3SOCD3, 300 K) δ (ppm) = 9.69 (s, 1h), 8.46 (d, j = 8.3 Hz, 1h), 8.02 - 7.97 (m, 2h), 7.77 (dd, j = 7.4, 8.3 Hz, 1h), 7.68 - 7.63 (m, 1h), 7.58 - 7.50 (m, 2h), 7.50 - 7.44 (m, 2h), 7.43 - 7.32 (m, 3h), 7.09 (d, j = 2.2 Hz, 1h). 7.00 (dd, j = 2.0, 8.5 hz, 1h), 6.94 (d, j = 8.4 hz, 1h), 5.80 (dd, j = 4.3, 10.5 hz, 1h), 5.36 (s, 2h), 4.37 (dd, j = 10.6, 14.3 hz, 1h), 4.16 (dd, j = 4.3, 14.3 hz, 1h), 4.02 (q, j = 7.0 hz, 1h), 3.74 (s, 1h), 3.32 (s, 1h), 3.03 (s, 1h), 2.19 (s, 1h), 1.32 (t, j = 6.9hz, 1h)). Example 9
[0062] Comparative Example (THF Batch Synthesis): A 100 mL EasyMax reactor was equipped with a temperature probe, reflux condenser, nitrogen inlet, and EasySampler probe; and compound B (6.00 g, 1.0 equivalent), THF (36 mL, 6.0 mL / g), and water (0.20 mL, 0.034 mL / g) were added sequentially. The reaction mixture was cooled to 15°C, and then acetic acid (15 mL, 2.5 mL / g) was slowly added over 2 minutes via syringe, maintaining the internal reaction temperature no higher than 25°C. The temperature was raised to 72°C, and compound A (4.6 g, 0.99 equivalent) was added as a solid. The reaction was maintained at 72°C for 21 hours, then cooled to 30°C and diluted with isopropyl acetate (51 mL, 8.5 mL / g). Then, a 10% sodium dihydrogen phosphate solution (30 mL, 5.0 mL / g) was added over 30 minutes via syringe pump, followed by an additional 30 minutes of stirring. The mixture was transferred to a separatory funnel and the aqueous layer was removed. The organic layer was washed twice more at 30°C with 10% sodium dihydrogen phosphate solution (30 mL, 5.0 mL / g) followed by water (30 mL, 5.0 mL / g). Isopropyl acetate (48 mL, 8.0 mL / g) was added, and the solvent was removed by rotary evaporation. The residue was concentrated again from the isopropyl acetate (48 mL, 8.0 mL / g) and absorbed in a clean 100 mL EasyMax reactor with isopropyl acetate (39 mL, 6.5 mL / g). The solution was heated to 35°C, and methyl tributyl ether (MTBE) (9.0 mL, 1.5 mL / g) was added; the mixture was stirred for 45 minutes until a turbid solution was obtained. MTBE (48 mL, 8.0 mL / g) was added via a syringe pump over a 2-hour period. After addition, the slurry was cooled to 15°C over 80 minutes and maintained at 15°C overnight. The resulting slurry was filtered, washed with MTBE (18.0 mL, 3.0 mL / g), and dried to provide crystalline apremilast (8.63 g, 97.2 wt%, 84% yield, determined by qNMR).
[0063] While this document provides examples of certain specific implementations, those skilled in the art will recognize that various changes and modifications are possible. Such modifications are also intended to fall within the scope of the appended patent applications.
[0064] none
[0065] none
Claims
1. A method for preparing apremilast, the method comprising: A first solution of (1) 3-acetaminophthalic anhydride (compound A) or a salt thereof contained in a first solvent and a second solution of (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonylmethane)ethyl-1-amine (compound B) or a salt thereof contained in a second solvent are mixed in a continuous reaction manner to form Apres in the reaction mixture, wherein the mixing occurs with a residence time of 0.1 to 120 minutes; And water is added to the reaction mixture to separate the apster.
2. The method of claim 1, wherein compound A or a salt thereof is present in an amount of 0.4 to 1.5 molar equivalents based on compound B or a salt thereof.
3. The method of claim 1, wherein compound A is not in salt form.
4. The method of claim 1, wherein the first solvent and the second solvent are the same solvent.
5. The method of claim 1, wherein the first solvent and the second solvent are different solvents.
6. The method of claim 1, wherein the first solvent is a polar aprotic solvent, or the second solvent is a polar aprotic solvent.
7. The method of claim 6, wherein the polar aprotic solvent is acetonitrile, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMAC), N-methyl-2-pyrrolidone (NMP), hexamethylphosphatidylamine (HMPA), N,N′-dimethylpropylideneurea (DMPU), cyclobutane, dihydro-L-glucosidone, 1,3-dimethyl-2-imidazolinone (DMI), or combinations thereof.
8. The method of claim 6, wherein the mixing is carried out in the presence of an acid.
9. The method of claim 8, wherein the acid is selected from the group consisting of: acetic acid, methanesulfonic acid, toluenesulfonic acid, trifluoroacetic acid, trichloroacetic acid, dichloroacetic acid, chloroacetic acid, benzenesulfonic acid, trifluoromethanesulfonic acid, ethylsulfonic acid, formic acid, propionic acid, benzoic acid, salicylic acid, and oxalic acid.
10. The method of claim 8, wherein the acid is present in a volume equivalent of 0.01 to 20 based on compound B or a salt thereof.
11. The method of claim 1, wherein the mixing is carried out in the presence of up to 1.5 molar equivalents of water based on compound B or a salt thereof.
12. The method of claim 1, wherein the mixing is carried out at 70°C to the temperature at which the first solvent or the second solvent is refluxed.
13. The method of claim 1, wherein the mixing occurs with a reaction time of 4 to 36 hours.
14. The method of claim 1, wherein the mixing occurs in a plug flow reactor.
15. The method of claim 1, wherein the separation comprises: a. Cool the reaction mixture to a temperature of 0°C to 50°C to form a cooled solution; b. Add water to the cooled solution; and c. Precipitate the aprestin from the solution formed in step (b) to separate the aprestin.
16. The method of claim 15, further comprising apström filtration of the precipitate of step (c).
17. The method of claim 15, wherein step (b) further comprises adding crystalline apremilast to the cooled solution such that the precipitate of step (c) produces crystalline apremilast.
18. The method of claim 1, wherein the separation comprises continuous crystallization using a mixed suspension mixed product exclusion (MSMPR) crystallizer; parallel filtration; or a combination thereof.
19. The method of claim 1, wherein the separation comprises: a. Cool the reaction mixture to a temperature of 0°C to 50°C to form a cooled solution; b. Add water to the cooled solution; and c. Precipitate Aprestin from the solution formed in step (b) to separate Aprestin.
20. A method for preparing apremilast, the method comprising: a. A first solution of 3-acetaminophen phthalic anhydride (compound A) contained in a first solvent and a second solution of (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonylurea)ethyl-1-amine (compound B) or a salt thereof contained in a second solvent are mixed to form Apres in the reaction mixture, wherein the mixing occurs in a continuous process apparatus; and b. separating the aprestin from the reaction mixture, wherein the separation comprises: i. cooling the reaction mixture to a temperature of 0°C to 50°C; ii. adding water to the cooled reaction mixture; iii. precipitating the aprestin from the mixture of step (ii); and iv. separating the precipitated aprestin.
21. A method for preparing crystalline apremilast, the method comprising: a. A first solution of 3-acetaminophen phthalic anhydride (compound A) contained in a first solvent and a second solution of (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonylurea)ethyl-1-amine (compound B) or a salt thereof contained in a second solvent are mixed to form apres in the reaction mixture, wherein the mixing occurs in a continuous process apparatus; and b. Crystallized apres is separated from the reaction mixture by continuous crystallization and parallel filtration.
22. The method as described in claim 21, wherein the continuous crystallization includes using a mixed suspension mixed product rejection (MSMPR) crystallizer.
Citation Information
Patent Citations
Process for preparation of apremilast and its intermediates
WO2016199031A1
Novel forms of apremilast and the process of making the same
WO2017039537A1
